Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells

European Cytokine Network

Volumn 21, Issue 3, 2010, Pages 154-164

  Hatfield, Kimberley Joanne ^a   Bedringsaas, Siv Lise ^b   Ryningen, Anita ^a   Gjertsen, Bjørn Tore ^a,b   Bruserud, Øystein ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

AML; Angiogenesis; Chemokine; HIF 1; Hypoxia; Oxygen tension

Indexed keywords

CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; OSTEOPONTIN; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LEUKEMIA CELL; MALE; OXYGEN TENSION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 77957335239     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2010.0204     Document Type: Article

References (43)

1. Harrison JS, Rameshwar P, Chang V, Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 2002; 99: 394.
2. Fiegl M, Samudio I, Clise-Dwyer K, et al. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2009; 113: 1504-12.
3. Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophys J 2001; 81: 675-84.
4. Guitart A, Hammoud M, Sbarba PD, Ivanovic Z, Praloran V. Slow cycling/quiescence balance of hematopoietic stem cells is related to physiological gradient of oxygen. Exp Hematol 2010 [Epub ahead of print].
5. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007; 104: 5431-6.
6. Winkler IG, Barbier V, Wadley R, et al. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: Serially reconstituting hematopoietic stem cells reside in distinct non-perfused niches. Blood 2010; 116: 375-85.
7. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; 2005: re12.
8. Lisy K, Peet DJ. Turn me on: regulating HIF transcriptional activity. Cell Death Differ 2008; 15: 642-9.
9. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-39.
10. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
11. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56: 5754-7.
12. de Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296-304.
13. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 2007; 62: 105-18.
14. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 2005; 5: 229-48.
15. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-13.
16. Demock K, Marinaro J, McInnis I, et al. Hypoxia-Inducible Factor-1 Alpha (HIF-1α) and HIF-2α Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML). Blood (ASH Annual Meeting Abstracts) 2008; 112: 2553.
17. LaIuppa JA, Papoutsakis ET, Miller WM. Oxygen tension alters the effects of cytokines on the megakaryocyte, erythrocyte, and granulocyte lineages. Exp Hematol 1998; 26: 835-43.
18. Ivanovic Z. Physiological, ex vivo cell oxygenation is necessary for a true insight into cytokine biology. Eur Cytokine Netw 2009; 20: 7-9.
19. Ryningen A, Stapnes C, Lassalle P, et al. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009; 33: 779-87.
20. Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells - the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001; 19: 1-11.
21. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003; 88: 416-28.
22. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004; 6: 33-43.
23. Bruserud O, Huang TS, Glenjen N, Gjertsen BT, Foss B. Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica 2002; 87: 584-95.
24. Liseth K, Ersvaer E, Abrahamsen JF, et al. Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells. Transfusion 2009; 49: 1709-19.
25. Motorin D, Bakken A, Foss Abrahamsen J, Ernst P, Bruserud O. Characterization of clonogenic progenitors in autologous peripheral blood stem cell grafts: evaluation of a simple in vitro assay suitable for routine clinical use. Hematology 2003; 8: 313-8.
26. Barber N, Belov L, Christopherson RI. All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias. Leuk Res 2008; 32: 315-22. (Pubitemid 351215530)
27. Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors. Ann N Y Acad Sci 2009; 1171: 321-33.
28. Ward JH, Jordan I, Kushner JP, Kaplan J. Heme regulation of HeLa cell transferrin receptor number. J Biol Chem 1984; 259: 13235-40. (Pubitemid 15223847)
29. Ryningen A, Stapnes C, Paulsen K, et al. In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs 2008; 17: 1623-33.
30. Zhang J, Song LP, Huang Y, et al. Accumulation of hypoxia-inducible factor-1 alpha protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica 2008; 93: 1480-7.
31. Bosco MC, Puppo M, Santangelo C, et al. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J Immunol 2006; 177: 1941-55. (Pubitemid 44092535)
32. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9 (Suppl 5): 10-7. (Pubitemid 39658341)
33. Bruserud O. IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Cytokines Cell Mol Ther 1998; 4: 187-98.
34. Jensen PO, Mortensen BT, Hodgkiss RJ, et al. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif 2000; 33: 381-95.
35. Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007; 92: 332-41. (Pubitemid 350143542)
36. Hatfield KJ, Hovland R, Oyan AM, et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008; 22: 287-93.
37. Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol 2007; 37: 2834-46. (Pubitemid 47578303)
38. Zhong H, Mabjeesh N, Willard M, Simons J. Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett 2002; 181: 233-8. (Pubitemid 34518309)
39. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-57.
40. Lee CY, Tien HF, Hou HA, Chou WC, Lin LI. Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. Br J Haematol 2008; 141: 736-9.
41. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch 2005; 450: 363-71.
42. Ivanovic Z, Dello Sbarba P, Trimoreau F, Faucher JL, Praloran V. Primitive human HPCs are better maintained and expanded in vitro at 1 percent oxygen than at 20 percent. Transfusion 2000; 40: 1482-8. (Pubitemid 32049053)
43. Song LP, Zhang J, Wu SF, et al. Hypoxia-inducible factor- 1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene 2008; 27: 519-27.